Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 47Terminated 4Withdrawn 3Recruiting 3Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Breast 1

Conditions

Small Cell Lung Carcinoma 1Lung Cancer Metastatic 1Breast Neoplasms 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × MLN 8237 × Clear all
NCT06095505 2026-02-17

ALISCA-Lung1

Puma Biotechnology, Inc.

Phase 2 Recruiting
80 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06369285 2025-12-10

ALISCA-Breast1

Puma Biotechnology, Inc.

Phase 2 Recruiting
150 enrolled
Breast

Breast Neoplasms

NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

University of California, San Francisco

Phase 1 Recruiting
38 enrolled
Thoracic

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡